With an extensive presence in North America, Europe, South America, Australia, New Zealand and South Africa and more recently in the MENA and ASEAN regions, Accord Healthcare has very rapidly become one of the fastest growing generic pharmaceutical companies. With a robust product portfolio in growth segments, such as Oncology, Cardiology, Neurology, Nephrology, Urology, Psychiatry, Diabetology, Pain management and Gastroenterology, Accord’s marketing and distribution network now reaches over 70 countries.
Accord has an extensive supply chain through its four UK based sites, helping to ensure a consistent supply of life-saving medicines for patients, whilst supporting customers to react quickly to dynamic market conditions.
Accord is committed to uncompromised quality for its products and services across the globe. Accord’s products are manufactured under the highest international standards and its manufacturing plants are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 55+ mid-to-late stage pipeline programs currently in development.
Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
Aptissen S.A. is a Swiss company based in Geneva area specialized in the development and commercialization of biopolymer-based medical devices. Aptissen’s founders have developed for the past 25 years the best quality injectable products which meet both patients and doctors expectations. It distributes its products through a worldwide international distributors network among more than 50 countries including Europe, South America, Canada, Middle East and Asia for instance.
Aptissen’s team revolutionized the viscosupplement market with Synolis VA and his patented formulation which combines Hyaluronic Acid and Sorbitol. Synolis VA provides rapid mobility recovery, fast long lasting pain relief associated with excellent safety.
Aptissen launched Synolis VA, an intra-articular injection product for osteoarthritis, the first Visco-Antalgic on the market, with a unique combination of Hyaluronic Acid and high concentration of Sorbitol administered in a single session.
Synolis VA’s viscoelastic properties (patented formulation) are similar to the young and healthy synovial fluid, resulting in rapid mobility recovery, fast and long-lasting pain relief associated with excellent safety as well as regeneration of cartilage.
As a result of over 75 years of experience in the pharmaceutical industry, Bagó Group is a market leader in both Argentina and Latin America. During 2002, Bagó Group expanded its operations to Asia, Africa and Eastern Europe.
In order to provide physicians and patients with the highest quality and therapeutic effectiveness pharmaceutical products, Bagó laboratories has carried out several major strategic ventures, joint ventures, co marketing agreements, and complement partnerships with outstanding international pharmaceutical companies.
This industrial structure is based on an inclusive and intelligent process, comprising logistics-the reception of raw materials- as the first step, to final approval of the finished product under all health standards. A state of the art technology, highly qualified staffs of professionals, the pharmacological development of Bagó own products (Alprazolam in sublingual administration and others), the constant scientific updating, and Bagó commitment in quality and therapeutic innovation, are the basis of this integral process.
Concordia International Corp. is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries.
Concordia’s International segment, formerly AMCo, consists of a diversified portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies. The Concordia International segment specializes in the acquisition, licensing and development of off-patent prescription medicines, which may be niche, hard-to-make products.
Farma-Derma s.r.l. is an Italian company that has been operating for years in the sector of healthcare, developing innovative products such as medical devices, food supplements and foods for special medical purposes mainly intended for the treatment of gynaecological, gastroenterological, dermatological, proctological, urological, otolaryngological and pulmonological pathologies.
Farma-Derma ’s mission it to develop very innovative formulations with the highest quality standards and its commitment is to offer safe and effective products to doctors and patients.
Farma-Derma s.r.l. sells its products directly in the Italian market and in more than 40 countries worldwide through a network of international business partners.
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: ‘Injectables,’ ‘Generics’ and ‘Branded’ based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. The Hikma Group consist of 29 manufacturing facilities located in 11 countries. Hikma’s global team consists of over 8000 employees. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.
HRA Pharma is a fast growing, innovative consumer healthcare company, empowering people throughout the world to improve their lives by developing accessible, value added, self-care solutions. Currently, the HRA Pharma portfolio encompasses four well-known consumer and OTC brands in blister care, lip care, emergency contraception and intimate care. With ambitious projects in the pipeline, including innovative Rx-to-OTC switches, HRA Pharma is committed to bringing a range of innovative products and services to market, particularly in areas of unmet customer needs. Headquartered in Paris, France with subsidiaries across Western Europe and a global network of local partners covering over 90 countries, the company has a proven structure, the skills and experience to capture new consumer healthcare businesses and deliver high quality brands on a global scale.
Labatec Pharma is a Swiss based company with strong presence in Switzerland and the MENA region. Our strategy is to expand our portfolio and presence through Development and In-licensing. Our focus is on the hospital market as well as the niche retail segment. Our Swiss base of manufacturing and product approvals is key to our top quality brand.
LEO Pharma helps people achieve healthy skin.
By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with over 1 500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 57th among Canada’s top 100 research & development (R&D) investors with over $44 million invested in 2015, Pharmascience Inc. is the 10th largest pharmaceutical company in Canada.
Pharmascience Inc. is a leading manufacturer and marketer of prescription; generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. Pharmascience Inc. commercializes nearly 400 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.
Sanofi Pasteur is a world leader in human vaccines. We produce a portfolio of high quality vaccines that matches our areas of expertise and ensure a sustainable future. We provide more than 1 billion doses of vaccines each year making it possible to immunize more than 500 million people worldwide per year.
Sanofi Pasteur produces a portfolio of high-quality vaccines that matches its areas of expertise:
- World’s largest producer of seasonal influenza vaccines: 200 million doses provided in 2016
- World’s leading provider of poliomyelitis vaccines
- Key player with a range of modern pediatric combination vaccines for both mature and emerging markets
The heritage of Sanofi Pasteur dates back more than a century, and is closely linked with the achievements of Louis Pasteur, the Mérieux family, John FitzGerald and Richard Slee.
Vifor Consumer Health AG is a company within the Galenica Group's Products & Brands business sector, our headquarters are located in Villars-sur-Glâne (Canton of Fribourg). We develop and market over-the-counter (OTC) medicines and parapharmaceutical products that are marketed exclusively in pharmacies and non-dispensing chemists in Switzerland and in over 25 countries worldwide. We also provide services in the marketing, distribution and supply chain management for OTC medicines, and parapharmaceutical products sectors as well as health and beauty products.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange.